Nature

169 articles in the TruthFoundry index. Each links out to the original.

• Phase 1b trial evaluates SER-155 biotherapeutic for transplant recipients · Researchers report phase 1b trial results for SER-155 live biotherapeutic for allo-HCT patients
• Nature Medicine publishes correction for multiple myeloma research article · Nature Medicine issued an official correction for a 2026 multiple myeloma research paper.
• Study maps microbiome responses to menopausal hormone therapy in women · Longitudinal Chinese cohort tracks multi-site microbiome changes during MHT treatment
• Author Correction Published for Phase 1 Gene Therapy Trial Article · Nature Medicine published corrections for a base editing gene therapy phase 1 trial paper.
• Pooled trial results published for engineered TIL therapy for resistant melanoma · Researchers report phase 1 and 1/2 trial data for amsoki-cel melanoma immunotherapy
• GBD 2023 study analyzes cervical cancer burden 1990-2023 with 2050 forecasts · Global Burden of Disease 2023 study documents cervical cancer trends and future projections.
• Phase 2 UNICORN trial tests neoadjuvant immunotherapies for colon cancer · UNICORN phase 2 trial evaluates botensilimab with or without balstilimab for colon cancer
• Phase 3 trials confirm povorcitinib efficacy for nonsegmental vitiligo · Two phase 3 STOP-V trials show oral povorcitinib delivers significant vitiligo repigmentation.
• Climate Change Threatens Malaria Elimination In The Asia Pacific · Cited research confirms climate change risks malaria elimination across the Asia Pacific region.
• Researchers develop digital twin framework to prevent preterm births · New digital twin framework may enable personalized preterm birth prevention interventions.
• Preclinical and phase 1 data support VG-3927 Alzheimer's drug candidate · Research identifies VG-3927 TREM2 agonist as promising Alzheimer's disease candidate
• Researchers introduce EVLF-FM explainable clinical vision language AI model · EVLF-FM medical foundation model delivers high accuracy with fine-grained explainability.
• PHERGain trial reports 5-year chemotherapy de-escalation outcomes for HER2+ breast cancer · Phase 2 PHERGain trial publishes 5-year survival and ctDNA findings for HER2-positive breast cancer
• Single-nucleus RNA atlas profiles early-onset colorectal cancer across age groups · Researchers generated an snRNA-seq atlas of 189 colorectal tumors spanning eight decades of patient age.
• Nature Medicine issues editorial concern over 2007 microRNA cardiac study · Nature Medicine published an editorial concern for a 2007 microRNA cardiac research paper.
• Author correction issued for toripalimab nasopharyngeal carcinoma phase 3 trial · An author correction was published for a toripalimab chemotherapy phase 3 clinical trial.
• Academic citation collection on metabolic heterogeneity of obesity · This content is a bibliography of research papers on obesity metabolic variation.
• Study identifies T cell immunity patterns linked to ALS progression · Research finds distinct blood and CSF T cell profiles correlate with ALS patient outcomes.
• Nature Medicine publishes author correction for aging clocks study · Nature Medicine corrected a surname spelling error in a published aging research paper.
• Author correction issued for pancreatic cancer liquid biopsy research · An author correction was published for pancreatic ductal adenocarcinoma liquid biopsy research
• Publisher correction issued for Our Future Health phenomic study · A publisher correction was published for the 1.9 million participant Our Future Health study paper
• Phase 2 MDT-BRIDGE trial reports durvalumab lung cancer treatment results · MDT-BRIDGE phase 2 trial evaluates durvalumab plus chemotherapy for resectable NSCLC.
• RELATIVITY-047 trial publishes 5-year advanced melanoma survival analysis · Phase 3 RELATIVITY-047 trial reports 5-year melanoma immunotherapy combination outcomes.
• Phase 2a GDFATHER-NEO trial tests nivolumab with visugromab for bladder cancer · GDFATHER-NEO phase 2a trial evaluates neoadjuvant nivolumab plus visugromab for muscle-invasive bladder cancer
• Conversational AI demonstrates feasibility in primary care trial · Patient-facing conversational AI showed safe feasibility in single-center primary care testing.
• Naive-like T cell levels predict CAR-T therapy outcomes in lymphoma patients · Multicenter trial analysis identifies naive-like T cells as top predictor of axi-cel CAR-T efficacy
• Phase 1/2 START-001 trial evaluates invikafusp alfa for solid tumors · Marengo Therapeutics details data sharing for the ongoing START-001 clinical trial.
• International scientists outline microbiome public health research priorities · HHS-convened scientists publish microbiome research strategy in Nature Medicine.
• Phase 2 AMPLIFY-7P trial evaluates camupepimut pancreatic cancer vaccine · Randomized phase 2 trial tested camupepimut vaccine for resected KRAS-mutated pancreatic cancer
• Nature Medicine publishes correction for 2012 colon cancer research paper · An author correction fixes a duplicated figure in a 2012 Nature Medicine colon cancer study.